Researchers from the School of Engineering at The Hong Kong University of Science and Technology (HKUST) have pioneered a ...

Biomea Fusion is a clinical-stage company focused on developing covalent small molecules for diabetes and genetically-defined cancers. The company highlighted positive phase 2 trial results for its ...

Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to ...

Researchers from the School of Engineering at The Hong Kong University of Science and Technology (HKUST) have pioneered a ...

EMERYVILLE, Calif., Oct. 27, 2022 /PRNewswire/ -- Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced ...

In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Matchpoint Therapeutics has been served $70 million in series A funds to fund its covalent molecule ambitions, prioritizing platform development and early discovery work. After raising $30 million in ...

CAMBRIDGE, England--(BUSINESS WIRE)--Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment ...